- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone ... Read More
When multiple myeloma relapses,Look to KYPROLIS®for the way forward
The International Myeloma Society recommends modifying treatment by considering a once-weekly regimen for appropriate RRMM patients to reduce the number of hospital/clinic visits during the COVID-19 pandemic.2
KRd as a triplet therapy
Kd 70 mg/m2 once weekly vs Kd 27 mg/m2 twice weekly. Kd 27 mg/m2 is not an FDA-approved dose for KYPROLIS®.1
Kd = KYPROLIS® (carfilzomib) and dexamethasone; KRd = KYPROLIS® (carfilzomib), lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone; RRMM = relapsed or refractory multiple myeloma; Vd = VELCADE® (bortezomib) and dexamethasone.